1. The evaluation of clinical efficacy and safety of polymyxin B in treatment of senile patients with hospital-acquired pneumonia caused by carbapenem-resistant bacteria
- Author
-
Jiong-He Wu, Ting-Ting Liu, Ya-Ping Yuan, Chao Wang, Xiang-Qun Fang, and Hong-Xia Li
- Subjects
lcsh:R5-920 ,carbapenem-resistant bacteria ,lcsh:R ,hospital-acquired pneumonia ,lcsh:Medicine ,polymyxin b ,tigecycline ,lcsh:Medicine (General) - Abstract
Objective To compare the efficacy and safety of polymyxin B and tigecycline in treatment of carbapenemresistant pneumonia in elderly patients. Methods This retrospective review involved 44 patients (≥85 years old) from January 2017 to December 2019. All the patients received meropenem in combination with polymyxin B or tigecycline divided into two groups. Group-wise general conditions, clinical efficacy, prognosis and adverse events were analyzed and compared, accordingly. Results A total of 20 patients in the polymyxin B group and 24 patients in the tigecycline group were included. The effective rate, bacterial clearance rate and thirty-day mortality of polymyxin B group were 65.0%, 30.0% and 25.0% respectively, with no significant difference from tigecycline group (58.3%, 20.8% and 20.8%)(P>0.05). Compared with tigecycline group, the elevated bilirubin incidence in polymyxin B group was significantly lower (10.0% vs. 41.7%, P0.05). Conclusion We found no significant difference in efficacy and thirty-day mortality between two groups. This study found for the first time that light may play a role in promoting skin pigmentation induced by polymyxin B. DOI: 10.11855/j.issn.0577-7402.2020.12.11
- Published
- 2020